3-Methyl-but-3-enoic acid isopropyl ester | 57003-43-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-Methyl-but-3-enoic acid isopropyl ester
• 英文别名: Propan-2-yl 3-methylbut-3-enoate
• CAS: 57003-43-7
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: OPWDTCJLWDPZQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  isopropyl 3-methyl-2-butenoate 在 N-溴代丁二酰亚胺(NBS) 作用下， 生成 3-Methyl-but-3-enoic acid isopropyl ester
  参考文献：
  名称：

  Sur la reaction de reformatsky

  摘要：

  DOI：

  10.1016/s0022-328x(00)83541-x

文献信息

• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：MANOHARAN Muthiah

  公开号：US20120027803A1

  公开（公告）日：2012-02-02

  The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其具有一个或多个可生物降解的基团，位于脂质部分（例如，疏水链）的中部或远端部分。这些阳离子脂质可以被纳入到脂质粒中，用于传递活性成分，例如核酸。本发明还涉及脂质粒，包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质，以及可选的固醇。脂质粒还可以包括治疗剂，例如核酸。
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE
  申请人：Sakamoto Kei

  公开号：US20100258764A1

  公开（公告）日：2010-10-14

  A polymerizable liquid crystal compound shown by the following formula (I), a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optical anisotropic article that includes the liquid crystalline polymer. The polymerizable liquid crystal compound shows a liquid crystal phase over a wider temperature range, is chemically stable, can be inexpensively produced, and has a wide selective reflection wavelength band Δλ (i.e., a large value Δn). The polymerizable liquid crystal composition includes the polymerizable liquid crystal compound, the liquid crystalline polymer is obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and the optical anisotropic article includes the liquid crystalline polymer. wherein Y 1 to Y 6 represent —O—, —O—C(═O)—, —C(═O)—O—, or the like, G 1 and G 2 represent divalent aliphatic groups having 1 to 20 carbon atoms, Z 1 and Z 2 represent an alkenyl group having 2 to 10 carbon atoms or the like, A 1 and A 2 represent divalent organic groups A having 1 to 30 carbon atoms, X 1 to X 8 represent a hydrogen atom or the like, and a and b represent 0 or 1.
• POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS
  申请人：Sakamoto Kei

  公开号：US20110140041A1

  公开（公告）日：2011-06-16

  A polymerizable liquid crystal compound shown by the following formula, a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optically anisotropic article that includes the liquid crystalline polymer, are disclosed. wherein Y 1 to Y 6 represent —O—C(═O)— or the like, G 1 and G 2 represent a divalent aliphatic group having 1 to 20 carbon atoms or the like, Z 1 and Z 2 represent an alkenyl group having 2 to 10 carbon atoms or the like, A 1 and A 2 represent a divalent organic group having 1 to 30 carbon atoms, M 1 and M 2 represent a substituted or unsubstituted 2,6-naphthylene group or a substituted or unsubstituted 1,4-phenylene group, provided that at least one of M 1 and M 2 represents a substituted or unsubstituted 2,6-naphthylene group, L 1 and L 2 represent a hydrogen atom or the like, and a and b are 0 or 1. A polymerizable liquid crystal compound that shows a liquid crystal phase over a wide temperature range, is chemically stable, can be produced inexpensively, and has a wide selective reflection wavelength band Δλ (i.e., a large value Δn); a polymerizable liquid crystal composition that includes the compound; a liquid crystalline polymer; and a optically anisotropic article that includes the liquid crystalline polymer as a constituting material; can be provided.
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM
  申请人：KATOH SHUNYA

  公开号：US20110237768A1

  公开（公告）日：2011-09-29

  A polymerizable liquid crystal compound represented by formula (I) is disclosed. R 0 and R 1 represent a hydrogen atom, or a C 1-4 alkyl group, provided that at least one of R 0 and R 1 represent a C 1-4 alkyl group; A 0 , A1, B 0 and B 1 represent a single bond, or a divalent linking group having a cyclic structure; X 0 , X 1 , Y 0 and Y 1 represent a single bond, —O—, —S—, —OCO—, —COO—, —OCOO—, —NR 2 CO—, —CONR 2 —, —OCONR 2 —, —NR 2 COO—, —NR 2 CONR 2 —, —C═N— or —N═C—; Q 0 and Q 1 a single bond or a divalent aliphatic group; Z 0 and Z 1 represent a hydrogen atom, cyano, halogen atom or polymerizable group; and n and m each independently represent an integer of from 0 to 2.
• LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20140308304A1

  公开（公告）日：2014-10-16

  The present invention relates to novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.